OncoMatch/Clinical Trials/NCT06748001

Avapritinib Rollover Study

Is NCT06748001 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Avapritinib for mastocytosis, systemic.

Phase 4RecruitingBlueprint Medicines CorporationNCT06748001Data as of Jun 2026Location: International · 6 countries

Treatment: Avapritinib — The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Targeted therapy

Avapritinib

Prior therapy

Must have received: avapritinib (avapritinib) — Blueprint Medicines sponsored avapritinib clinical study

Participated in a Blueprint Medicines sponsored avapritinib clinical study

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06748001 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received avapritinib.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify